UNSPSC 51203404: Mercaptopurine anhydrous

This classification denotes a purine antagonist and immunosuppressant C5H4N4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PKK6MUZ20G, chemically known as 1,9-dihydro-6h-purine-6-thione, but more generally known as mercaptopurine anhydrous, which bears US NIH Compound Identifier 667490. Most nations, for tariff and trade purposes, schedule mercaptopurine anhydrous under HS 29335995 and SITC 51576. As of Q4 2014, MERCAPTOPURINE ANHYDROUS remains US FDA's Preferred Term for this commodity.

Mercaptopurine anhydrous bears US NLM identifiers UMLS ID C1881785 and NCI Concept Code C61832. SMILES: C1[NH]C2C(N1)C(=S)[NH]CN2.

UNSPSC 51203404 Mercaptopurine anhydrous, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two opportunities in the recent record—an Illinois Department of Public Health pharmaceutical warehouse piggyback contract awarded to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and a Seminole County, Florida IFB for Naloxone and drug deactivation systems—are not for mercaptopurine anhydrous or related pharmaceutical active ingredients. State and local health departments and counties do purchase pharmaceutical products through cooperative purchasing vehicles and competitive bidding, but the available records do not show current demand for this specific commodity.

The geographic spread of pharmaceutical procurement activity appears concentrated in Florida and Illinois based on recent notices, though this sample is too narrow to characterize broader state or regional patterns for this code specifically. Without current open solicitations or recent awards for mercaptopurine anhydrous, the code presents limited near-term pursuit opportunity. Vendors serving state and local health systems, public health departments, and county health facilities should monitor cooperative purchasing consortia such as MMCAP and state-level pharmaceutical cooperative agreements for potential future demand, but the current activity record does not support active business development focus on this commodity code.